Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

27 januari 2021 bijgewerkt door: Novartis Pharmaceuticals

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.

Studie Overzicht

Toestand

Voltooid

Conditie

Eierstokkanker

Interventie / Behandeling

Gedetailleerde beschrijving

This was a randomized, two-arm, placebo controlled, double-blind, multicenter, intergroup Phase III study in women with non-bulky FIGO (International Federation of Gynecology and Obstetrics) Stage II - IV ovarian, fallopian tube, or primary peritoneal cancer that had not progressed (i.e., complete response (CR), partial response (PR), stable disease (SD) after completing their first-line chemotherapy for advanced ovarian cancer. Approximately 900 subjects were to be enrolled into the study. Study was closed following 3rd overall survival (OS) interim analysis as planned per protocol, which confirmed futility.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

940

Fase

Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Australië
- - Melbourne, Australië, 3084
    - Novartis Investigative Site
- New South Wales
  - Camperdown, New South Wales, Australië, 2050
    - Novartis Investigative Site
  - Liverpool, New South Wales, Australië, 2170
    - Novartis Investigative Site
  - Randwick, New South Wales, Australië, 2031
    - Novartis Investigative Site
  - Waratah, New South Wales, Australië, 2298
    - Novartis Investigative Site
- Queensland
  - Herston, Queensland, Australië, 4029
    - Novartis Investigative Site
  - South Brisbane, Queensland, Australië, 4101
    - Novartis Investigative Site
- South Australia
  - Adelaide, South Australia, Australië, 5000
    - Novartis Investigative Site
- Tasmania
  - Hobart, Tasmania, Australië, 7000
    - Novartis Investigative Site
- Victoria
  - Malvern, Victoria, Australië, 3144
    - Novartis Investigative Site
  - Parkville, Victoria, Australië, 3052
    - Novartis Investigative Site
  - Wodonga, Victoria, Australië, 3690
    - Novartis Investigative Site
- Western Australia
  - Nedlands, Western Australia, Australië, 6009
    - Novartis Investigative Site
België
- - Bonheiden, België, 2820
    - Novartis Investigative Site
  - Duffel, België, 2570
    - Novartis Investigative Site
  - Gent, België, 9000
    - Novartis Investigative Site
  - Kortrijk, België, 8500
    - Novartis Investigative Site
  - Leuven, België, 3000
    - Novartis Investigative Site
  - Libramont, België, 6800
    - Novartis Investigative Site
  - Liege, België, 4000
    - Novartis Investigative Site
  - Namur, België, 5000
    - Novartis Investigative Site
  - Oostende, België, 8400
    - Novartis Investigative Site
China
- - Beijing, China, 100044
    - Novartis Investigative Site
  - Beijing, China, 100021
    - Novartis Investigative Site
  - Beijing, China, 100853
    - Novartis Investigative Site
  - Beijing, China, 100141
    - Novartis Investigative Site
  - Shanghai, China, 200032
    - Novartis Investigative Site
  - Shanghai, China, 200011
    - Novartis Investigative Site
  - Tianjin, China, 300060
    - Novartis Investigative Site
- Guangdong
  - Guangzhou, Guangdong, China
    - Novartis Investigative Site
- Jiangsu
  - Nanjing, Jiangsu, China, 210009
    - Novartis Investigative Site
- Liaoning
  - Shenyang, Liaoning, China, 110022
    - Novartis Investigative Site
- Shandong
  - Jinan, Shandong, China, 250012
    - Novartis Investigative Site
- Zhejiang
  - Hangzhou, Zhejiang, China, 310006
    - Novartis Investigative Site
  - Hangzhou, Zhejiang, China, 310022
    - Novartis Investigative Site
Denemarken
- - Aalborg, Denemarken, 9100
    - Novartis Investigative Site
  - Herlev, Denemarken, DK-2730
    - Novartis Investigative Site
  - Herning, Denemarken, 7400
    - Novartis Investigative Site
  - Koebenhavn Oe, Denemarken, 2100
    - Novartis Investigative Site
Duitsland
- - Berlin, Duitsland, 10367
    - Novartis Investigative Site
  - Berlin, Duitsland, 13589
    - Novartis Investigative Site
  - Berlin, Duitsland, 13353
    - Novartis Investigative Site
  - Berlin, Duitsland, 12683
    - Novartis Investigative Site
  - Hamburg, Duitsland, 20246
    - Novartis Investigative Site
  - Hamburg, Duitsland, 20095
    - Novartis Investigative Site
  - Hamburg, Duitsland, 22087
    - Novartis Investigative Site
- Baden-Wuerttemberg
  - Esslingen, Baden-Wuerttemberg, Duitsland, 73730
    - Novartis Investigative Site
  - Freiburg, Baden-Wuerttemberg, Duitsland, 79106
    - Novartis Investigative Site
  - Freiburg, Baden-Wuerttemberg, Duitsland, 79098
    - Novartis Investigative Site
  - Karlsruhe, Baden-Wuerttemberg, Duitsland, 76133
    - Novartis Investigative Site
  - Karlsruhe, Baden-Wuerttemberg, Duitsland, 76135
    - Novartis Investigative Site
  - Mannheim, Baden-Wuerttemberg, Duitsland, 68167
    - Novartis Investigative Site
  - Mutlangen, Baden-Wuerttemberg, Duitsland, 73557
    - Novartis Investigative Site
  - Reutlingen, Baden-Wuerttemberg, Duitsland, 72764
    - Novartis Investigative Site
  - Schwaebisch Hall, Baden-Wuerttemberg, Duitsland, 74523
    - Novartis Investigative Site
  - Tuebingen, Baden-Wuerttemberg, Duitsland, 72076
    - Novartis Investigative Site
  - Ulm, Baden-Wuerttemberg, Duitsland, 89075
    - Novartis Investigative Site
- Bayern
  - Bayreuth, Bayern, Duitsland, 95445
    - Novartis Investigative Site
  - Coburg, Bayern, Duitsland, 96450
    - Novartis Investigative Site
  - Deggendorf, Bayern, Duitsland, 94469
    - Novartis Investigative Site
  - Ebersberg, Bayern, Duitsland, 85560
    - Novartis Investigative Site
  - Eggenfelden, Bayern, Duitsland, 84307
    - Novartis Investigative Site
  - Fuerth, Bayern, Duitsland, 90766
    - Novartis Investigative Site
  - Muenchen, Bayern, Duitsland, 80637
    - Novartis Investigative Site
  - Muenchen, Bayern, Duitsland, 81675
    - Novartis Investigative Site
  - Muenchen, Bayern, Duitsland, 81377
    - Novartis Investigative Site
  - Schweinfurt, Bayern, Duitsland, 97422
    - Novartis Investigative Site
- Hessen
  - Darmstadt, Hessen, Duitsland, 64283
    - Novartis Investigative Site
  - Frankfurt, Hessen, Duitsland, 65929
    - Novartis Investigative Site
  - Frankfurt am Main, Hessen, Duitsland, 60590
    - Novartis Investigative Site
  - Fulda, Hessen, Duitsland, 36043
    - Novartis Investigative Site
  - Kassel, Hessen, Duitsland, 34125
    - Novartis Investigative Site
  - Lich, Hessen, Duitsland, 35423
    - Novartis Investigative Site
  - Limburg, Hessen, Duitsland, 65549
    - Novartis Investigative Site
  - Marburg, Hessen, Duitsland, 35043
    - Novartis Investigative Site
  - Offenbach, Hessen, Duitsland, 63069
    - Novartis Investigative Site
  - Offenbach, Hessen, Duitsland, 63065
    - Novartis Investigative Site
  - Wiesbaden, Hessen, Duitsland, 65199
    - Novartis Investigative Site
  - Wiesbaden, Hessen, Duitsland, 65189
    - Novartis Investigative Site
- Mecklenburg-Vorpommern
  - Greifswald, Mecklenburg-Vorpommern, Duitsland, 17475
    - Novartis Investigative Site
  - Rostock, Mecklenburg-Vorpommern, Duitsland, 18059
    - Novartis Investigative Site
- Niedersachsen
  - Braunschweig, Niedersachsen, Duitsland, 38100
    - Novartis Investigative Site
  - Cuxhaven, Niedersachsen, Duitsland, 27474
    - Novartis Investigative Site
  - Georgsmarienhuette, Niedersachsen, Duitsland, 49124
    - Novartis Investigative Site
  - Gifhorn, Niedersachsen, Duitsland, 38518
    - Novartis Investigative Site
  - Goettingen, Niedersachsen, Duitsland, 37075
    - Novartis Investigative Site
  - Goslar, Niedersachsen, Duitsland, 38642
    - Novartis Investigative Site
  - Hannover, Niedersachsen, Duitsland, 30625
    - Novartis Investigative Site
  - Hannover, Niedersachsen, Duitsland, 30177
    - Novartis Investigative Site
  - Hannover, Niedersachsen, Duitsland, 30169
    - Novartis Investigative Site
  - Hildesheim, Niedersachsen, Duitsland, 31134
    - Novartis Investigative Site
  - Leer, Niedersachsen, Duitsland, 26789
    - Novartis Investigative Site
  - Lueneburg, Niedersachsen, Duitsland, 21339
    - Novartis Investigative Site
  - Oldenburg, Niedersachsen, Duitsland, 26121
    - Novartis Investigative Site
  - Salzgitter, Niedersachsen, Duitsland, 38226
    - Novartis Investigative Site
  - Wolfsburg, Niedersachsen, Duitsland, 38440
    - Novartis Investigative Site
- Nordrhein-Westfalen
  - Bonn, Nordrhein-Westfalen, Duitsland, 53127
    - Novartis Investigative Site
  - Bonn, Nordrhein-Westfalen, Duitsland, 53113
    - Novartis Investigative Site
  - Bonn, Nordrhein-Westfalen, Duitsland, 053123
    - Novartis Investigative Site
  - Bonn, Nordrhein-Westfalen, Duitsland, 53111
    - Novartis Investigative Site
  - Detmold, Nordrhein-Westfalen, Duitsland, 32756
    - Novartis Investigative Site
  - Dortmund, Nordrhein-Westfalen, Duitsland, 44137
    - Novartis Investigative Site
  - Duesseldorf, Nordrhein-Westfalen, Duitsland, 40225
    - Novartis Investigative Site
  - Essen, Nordrhein-Westfalen, Duitsland, 45122
    - Novartis Investigative Site
  - Essen, Nordrhein-Westfalen, Duitsland, 45136
    - Novartis Investigative Site
  - Essen, Nordrhein-Westfalen, Duitsland, 45147
    - Novartis Investigative Site
  - Koeln, Nordrhein-Westfalen, Duitsland, 50937
    - Novartis Investigative Site
  - Neuss, Nordrhein-Westfalen, Duitsland, 41464
    - Novartis Investigative Site
  - Troisdorf, Nordrhein-Westfalen, Duitsland, 53840
    - Novartis Investigative Site
  - Viersen, Nordrhein-Westfalen, Duitsland, 41747
    - Novartis Investigative Site
- Rheinland-Pfalz
  - Mainz, Rheinland-Pfalz, Duitsland, 55131
    - Novartis Investigative Site
  - Trier, Rheinland-Pfalz, Duitsland, 54290
    - Novartis Investigative Site
- Sachsen
  - Chemnitz, Sachsen, Duitsland, 09116
    - Novartis Investigative Site
  - Dresden, Sachsen, Duitsland, 01127
    - Novartis Investigative Site
  - Dresden, Sachsen, Duitsland, 01307
    - Novartis Investigative Site
  - Leipzg, Sachsen, Duitsland, 04109
    - Novartis Investigative Site
  - Radebeul, Sachsen, Duitsland, 01445
    - Novartis Investigative Site
  - Zwickau, Sachsen, Duitsland, 08060
    - Novartis Investigative Site
- Sachsen-Anhalt
  - Halle, Sachsen-Anhalt, Duitsland, 06120
    - Novartis Investigative Site
  - Magdeburg, Sachsen-Anhalt, Duitsland, 39108
    - Novartis Investigative Site
  - Magdeburg, Sachsen-Anhalt, Duitsland, 39110
    - Novartis Investigative Site
  - Quedlinburg, Sachsen-Anhalt, Duitsland, 06484
    - Novartis Investigative Site
  - Salzwedel, Sachsen-Anhalt, Duitsland, 29410
    - Novartis Investigative Site
- Schleswig-Holstein
  - Flensburg, Schleswig-Holstein, Duitsland, 24939
    - Novartis Investigative Site
  - Kiel, Schleswig-Holstein, Duitsland, 24105
    - Novartis Investigative Site
  - Luebeck, Schleswig-Holstein, Duitsland, 23538
    - Novartis Investigative Site
- Thueringen
  - Gera, Thueringen, Duitsland, 07548
    - Novartis Investigative Site
  - Nordhausen, Thueringen, Duitsland, 99734
    - Novartis Investigative Site
  - Suhl, Thueringen, Duitsland, 98527
    - Novartis Investigative Site
Frankrijk
- - ANGERS Cedex 2, Frankrijk, 49055
    - Novartis Investigative Site
  - Avignon cedex, Frankrijk, 84902
    - Novartis Investigative Site
  - Besancon Cedex, Frankrijk, 25030
    - Novartis Investigative Site
  - Bordeaux, Frankrijk, 33000
    - Novartis Investigative Site
  - Bordeaux, Frankrijk, 33076
    - Novartis Investigative Site
  - Bordeaux, Frankrijk, 33300
    - Novartis Investigative Site
  - Bourg en Bresse Cedex, Frankrijk, 01012
    - Novartis Investigative Site
  - Brest Cedex, Frankrijk, 29609
    - Novartis Investigative Site
  - Brive La Gaillarde, Frankrijk, 19100
    - Novartis Investigative Site
  - Caen Cedex 05, Frankrijk, 14076
    - Novartis Investigative Site
  - Clermont-Ferrand cedex, Frankrijk, 63011
    - Novartis Investigative Site
  - Colmar Cedex, Frankrijk, 68024
    - Novartis Investigative Site
  - Dax Cedex, Frankrijk, 40107
    - Novartis Investigative Site
  - Grenoble Cedex, Frankrijk, 38028
    - Novartis Investigative Site
  - Grenoble Cedex 09, Frankrijk, 38043
    - Novartis Investigative Site
  - La Roche sur Yon Cedex 9, Frankrijk, 85925
    - Novartis Investigative Site
  - Le Chesnay Cedex, Frankrijk, 78157
    - Novartis Investigative Site
  - Le Mans, Frankrijk, 72015
    - Novartis Investigative Site
  - Lille, Frankrijk, 59037
    - Novartis Investigative Site
  - Lille Cedex, Frankrijk, 59020
    - Novartis Investigative Site
  - Lorient cedex, Frankrijk, 56322
    - Novartis Investigative Site
  - Lyon Cedex 08, Frankrijk, 69373
    - Novartis Investigative Site
  - Marseille cedex, Frankrijk, 13008
    - Novartis Investigative Site
  - Metz Cedex 03, Frankrijk, 57085
    - Novartis Investigative Site
  - Mont de Marsan, Frankrijk, 40024
    - Novartis Investigative Site
  - Montpellier, Frankrijk, 34070
    - Novartis Investigative Site
  - Montpellier cedex 5, Frankrijk, 34298
    - Novartis Investigative Site
  - Mougins Cedex 2, Frankrijk, 06250
    - Novartis Investigative Site
  - Nancy, Frankrijk, 54100
    - Novartis Investigative Site
  - Nantes Cedex 2, Frankrijk, 44277
    - Novartis Investigative Site
  - Nice Cedex 2, Frankrijk, 06189
    - Novartis Investigative Site
  - Nimes, Frankrijk, 30907
    - Novartis Investigative Site
  - Orleans, Frankrijk, 45100
    - Novartis Investigative Site
  - Paris, Frankrijk, 75014
    - Novartis Investigative Site
  - Paris, Frankrijk, 75012
    - Novartis Investigative Site
  - Paris Cedex 10, Frankrijk, 75475
    - Novartis Investigative Site
  - Paris Cedex 20, Frankrijk, 75970
    - Novartis Investigative Site
  - Paris Cedex 4, Frankrijk, 75181
    - Novartis Investigative Site
  - Paris cedex 05, Frankrijk, 75248
    - Novartis Investigative Site
  - Perigueux Cedex, Frankrijk, 24004
    - Novartis Investigative Site
  - Perin Sur Mer, Frankrijk, 22190
    - Novartis Investigative Site
  - Pierre-Benite Cedex, Frankrijk, 69495
    - Novartis Investigative Site
  - Reims Cedex, Frankrijk, 51056
    - Novartis Investigative Site
  - Rouen, Frankrijk, 76000
    - Novartis Investigative Site
  - Saint-Herblain, Frankrijk, 44805
    - Novartis Investigative Site
  - Saint-Priest en Jarez, Frankrijk, 42271
    - Novartis Investigative Site
  - Strasbourg, Frankrijk, 67000
    - Novartis Investigative Site
  - Strasbourg Cedex, Frankrijk, 67091
    - Novartis Investigative Site
  - Suresnes, Frankrijk, 92151
    - Novartis Investigative Site
  - Thonon-les-Bains, Frankrijk, 74203
    - Novartis Investigative Site
  - Vandoeuvre-Les-Nancy, Frankrijk, 54511
    - Novartis Investigative Site
Hongkong
- - Hong Kong, Hongkong
    - Novartis Investigative Site
  - Kowloon, Hongkong
    - Novartis Investigative Site
Ierland
- - Dublin, Ierland, 7
    - Novartis Investigative Site
  - Dublin, Ierland, 8
    - Novartis Investigative Site
  - Dublin, Ierland, 9
    - Novartis Investigative Site
  - Dublin, Ierland, 4
    - Novartis Investigative Site
  - Waterford, Ierland
    - Novartis Investigative Site
  - Wilton, Cork, Ierland
    - Novartis Investigative Site
Italië
- Basilicata
  - Potenza, Basilicata, Italië, 85100
    - Novartis Investigative Site
- Campania
  - Avellino, Campania, Italië, 83100
    - Novartis Investigative Site
  - Napoli, Campania, Italië, 80131
    - Novartis Investigative Site
- Emilia-Romagna
  - Bologna, Emilia-Romagna, Italië, 40138
    - Novartis Investigative Site
  - Bologna, Emilia-Romagna, Italië, 40139
    - Novartis Investigative Site
  - Carpi (MO), Emilia-Romagna, Italië, 41012
    - Novartis Investigative Site
  - Faenza (RA), Emilia-Romagna, Italië, 48018
    - Novartis Investigative Site
  - Reggio Emilia, Emilia-Romagna, Italië, 42100
    - Novartis Investigative Site
- Friuli-Venezia-Giulia
  - Aviano (PN), Friuli-Venezia-Giulia, Italië, 33081
    - Novartis Investigative Site
- Lazio
  - Roma, Lazio, Italië, 00168
    - Novartis Investigative Site
  - Roma, Lazio, Italië, 00144
    - Novartis Investigative Site
  - Roma, Lazio, Italië, 00186
    - Novartis Investigative Site
- Lombardia
  - Brescia, Lombardia, Italië
    - Novartis Investigative Site
  - Como, Lombardia, Italië, 22100
    - Novartis Investigative Site
  - Milano, Lombardia, Italië, 20133
    - Novartis Investigative Site
  - Milano, Lombardia, Italië, 20141
    - Novartis Investigative Site
  - Milano, Lombardia, Italië, 20162
    - Novartis Investigative Site
  - Milano, Lombardia, Italië, 20132
    - Novartis Investigative Site
  - Milano, Lombardia, Italië, 20122
    - Novartis Investigative Site
  - Monza, Lombardia, Italië, 20052
    - Novartis Investigative Site
  - Sondrio, Lombardia, Italië, 23100
    - Novartis Investigative Site
  - Varese, Lombardia, Italië, 21100
    - Novartis Investigative Site
- Molise
  - Campobasso, Molise, Italië, 86100
    - Novartis Investigative Site
- Piemonte
  - Torino, Piemonte, Italië, 10126
    - Novartis Investigative Site
  - Torino, Piemonte, Italië, 10128
    - Novartis Investigative Site
- Puglia
  - Bari, Puglia, Italië, 70124
    - Novartis Investigative Site
- Sicilia
  - Palermo, Sicilia, Italië, 90146
    - Novartis Investigative Site
- Umbria
  - Perugia, Umbria, Italië, 06132
    - Novartis Investigative Site
- Veneto
  - Vicenza, Veneto, Italië, 36100
    - Novartis Investigative Site
Japan
- - Ehime, Japan, 791-0280
    - Novartis Investigative Site
  - Fukuoka, Japan, 811-1395
    - Novartis Investigative Site
  - Hiroshima, Japan, 734-8551
    - Novartis Investigative Site
  - Hiroshima, Japan, 737-0023
    - Novartis Investigative Site
  - Hokkaido, Japan, 060-8648
    - Novartis Investigative Site
  - Iwate, Japan, 020-8505
    - Novartis Investigative Site
  - Kagoshima, Japan, 890-8760
    - Novartis Investigative Site
  - Miyagi, Japan, 980-8574
    - Novartis Investigative Site
  - Osaka, Japan, 589-8511
    - Novartis Investigative Site
  - Saitama, Japan, 350-1298
    - Novartis Investigative Site
  - Tokyo, Japan, 104-0045
    - Novartis Investigative Site
  - Tokyo, Japan, 160-8582
    - Novartis Investigative Site
  - Tokyo, Japan, 105-8471
    - Novartis Investigative Site
  - Tokyo, Japan, 125-8506
    - Novartis Investigative Site
  - Tottori, Japan, 683-8504
    - Novartis Investigative Site
Korea, republiek van
- - Goyang-si, Gyeonggi-do, Korea, republiek van, 410-769
    - Novartis Investigative Site
  - Kangnam-Ku ,Seoul, Korea, republiek van, (135-702)
    - Novartis Investigative Site
  - Seoul, Korea, republiek van, 03080
    - Novartis Investigative Site
  - Seoul, Korea, republiek van, 138-736
    - Novartis Investigative Site
  - Seoul, Korea, republiek van, 135-710
    - Novartis Investigative Site
Noorwegen
- - Bergen, Noorwegen, 5021
    - Novartis Investigative Site
  - Oslo, Noorwegen, 0310
    - Novartis Investigative Site
  - Stavanger, Noorwegen, 4011
    - Novartis Investigative Site
  - Tromso, Noorwegen, 9038
    - Novartis Investigative Site
Oostenrijk
- - Graz, Oostenrijk, A-8036
    - Novartis Investigative Site
  - Graz, Oostenrijk, 8020
    - Novartis Investigative Site
  - Innsbruck, Oostenrijk, 6020
    - Novartis Investigative Site
  - Klagenfurt Am Woerthersee, Oostenrijk, 9020
    - Novartis Investigative Site
  - Korneuburg, Oostenrijk, 2100
    - Novartis Investigative Site
  - Krems, Oostenrijk, 3500
    - Novartis Investigative Site
  - Leoben, Oostenrijk, 8700
    - Novartis Investigative Site
  - Linz, Oostenrijk, 4020
    - Novartis Investigative Site
  - Linz, Oostenrijk, 4010
    - Novartis Investigative Site
  - Oberpullendorf, Oostenrijk, 7350
    - Novartis Investigative Site
  - Wien, Oostenrijk, 1090
    - Novartis Investigative Site
  - Wien, Oostenrijk, 1130
    - Novartis Investigative Site
  - Wien, Oostenrijk, 1160
    - Novartis Investigative Site
Spanje
- - Alcorcon (Madrid), Spanje, 28922
    - Novartis Investigative Site
  - Barcelona, Spanje, 08025
    - Novartis Investigative Site
  - Barcelona, Spanje, 08003
    - Novartis Investigative Site
  - Barcelona, Spanje, 08907
    - Novartis Investigative Site
  - Barcelona, Spanje, 080018
    - Novartis Investigative Site
  - Cartagena (Murcia), Spanje, 30203
    - Novartis Investigative Site
  - Elche, Spanje, 03203
    - Novartis Investigative Site
  - Lerida, Spanje, 25198
    - Novartis Investigative Site
  - Madrid, Spanje, 28034
    - Novartis Investigative Site
  - Madrid, Spanje, 28046
    - Novartis Investigative Site
  - Madrid, Spanje, 28007
    - Novartis Investigative Site
  - Madrid, Spanje, 28033
    - Novartis Investigative Site
  - Madrid, Spanje, 28050
    - Novartis Investigative Site
  - Murcia (El Palmar), Spanje, 30120
    - Novartis Investigative Site
  - Palma de Mallorca, Spanje, 07198
    - Novartis Investigative Site
  - Pamplona, Spanje, 31008
    - Novartis Investigative Site
  - Sabadell (Barcelona), Spanje, 08208
    - Novartis Investigative Site
  - San Sebastian, Spanje, 20014
    - Novartis Investigative Site
  - Santiago de Compostela, Spanje, 15706
    - Novartis Investigative Site
  - Terrassa, Spanje, 08227
    - Novartis Investigative Site
  - Valencia, Spanje, 46014
    - Novartis Investigative Site
  - Valencia, Spanje, 46009
    - Novartis Investigative Site
  - Zaragoza, Spanje, 50009
    - Novartis Investigative Site
Taiwan
- - Taipei, Taiwan, 104
    - Novartis Investigative Site
  - Taipei, Taiwan, 112
    - Novartis Investigative Site
Verenigde Staten
- California
  - Anaheim, California, Verenigde Staten, 92807
    - Novartis Investigative Site
  - Baldwin Park, California, Verenigde Staten, 91706
    - Novartis Investigative Site
  - Bellflower, California, Verenigde Staten, 90706
    - Novartis Investigative Site
  - Duarte, California, Verenigde Staten, 91010
    - Novartis Investigative Site
  - Fontana, California, Verenigde Staten, 92335
    - Novartis Investigative Site
  - Hayward, California, Verenigde Staten, 94545
    - Novartis Investigative Site
  - Irvine, California, Verenigde Staten, 92618
    - Novartis Investigative Site
  - Long Beach, California, Verenigde Staten, 90806
    - Novartis Investigative Site
  - Los Angeles, California, Verenigde Staten, 90027
    - Novartis Investigative Site
  - Los Angeles, California, Verenigde Staten, 90095
    - Novartis Investigative Site
  - Los Angeles, California, Verenigde Staten, 90034
    - Novartis Investigative Site
  - Oakland, California, Verenigde Staten, 94611
    - Novartis Investigative Site
  - Ontario, California, Verenigde Staten, 91761
    - Novartis Investigative Site
  - Orange, California, Verenigde Staten, 92868
    - Novartis Investigative Site
  - Panorama City, California, Verenigde Staten, 91402
    - Novartis Investigative Site
  - Riverside, California, Verenigde Staten, 92505
    - Novartis Investigative Site
  - Roseville, California, Verenigde Staten, 95661
    - Novartis Investigative Site
  - Sacramento, California, Verenigde Staten, 95817
    - Novartis Investigative Site
  - Sacramento, California, Verenigde Staten, 95825
    - Novartis Investigative Site
  - San Diego, California, Verenigde Staten, 92120
    - Novartis Investigative Site
  - San Diego, California, Verenigde Staten, 92108
    - Novartis Investigative Site
  - San Francisco, California, Verenigde Staten, 94115
    - Novartis Investigative Site
  - San Jose, California, Verenigde Staten, 95119-1110
    - Novartis Investigative Site
  - Santa Clara, California, Verenigde Staten, 95051
    - Novartis Investigative Site
  - South San Francisco, California, Verenigde Staten, 94080
    - Novartis Investigative Site
  - Vallejo, California, Verenigde Staten, 94589
    - Novartis Investigative Site
  - Walnut Creek, California, Verenigde Staten, 94596
    - Novartis Investigative Site
  - Woodland Hills, California, Verenigde Staten, 91367
    - Novartis Investigative Site
- Georgia
  - Augusta, Georgia, Verenigde Staten, 30912
    - Novartis Investigative Site
- New Jersey
  - Morristown, New Jersey, Verenigde Staten, 07962-1956
    - Novartis Investigative Site
- New York
  - Bronx, New York, Verenigde Staten, 10461
    - Novartis Investigative Site
  - New York, New York, Verenigde Staten, 10032
    - Novartis Investigative Site
  - New York, New York, Verenigde Staten, 10065
    - Novartis Investigative Site
- Texas
  - Houston, Texas, Verenigde Staten, 77030
    - Novartis Investigative Site
- Virginia
  - Annandale, Virginia, Verenigde Staten, 22003
    - Novartis Investigative Site
Zweden
- - Linkoping, Zweden, SE-581 85
    - Novartis Investigative Site
  - Lund, Zweden, SE-221 85
    - Novartis Investigative Site
  - Stockholm, Zweden, SE-171 76
    - Novartis Investigative Site
  - Uppsala, Zweden, SE-751 85
    - Novartis Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

written informed consent
At least 18 years old.
Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
No evidence of disease progression
ECOG status of 0 or 2
Able to swallow and retain oral medication.
Adequate hematologic, hepatic, and renal system function as follows:

Hematologic

Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
Platelets at least 100 X 10^9/L
Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
Total bilirubin up to 1.5 X ULN
AST and ALT up to 2.5 X ULN Renal
Serum creatinine up to 1.5 mg/dL

Or, if greater than 1.5 mg/dL:

Calculated creatinine clearance at least 50 mL/min Urine Protein

Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24- hour urine protein analysis.
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.

Exclusion Criteria:

Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
Clinically significant gastrointestinal abnormalities
Prolongation of corrected QT interval (QTc) > 480 msecs
History of any one or more cardiovascular conditions within the past 6 months prior to randomization
Cardiac angioplasty or stenting
Myocardial infarction
Unstable angina
Symptomatic peripheral vascular disease
- Class III or IV congestive heart failure
Poorly controlled hypertension
History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
Evidence of active bleeding or bleeding diathesis.
Hemoptysis within 6 weeks prior to randomization.
Endobronchial metastases.
Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
Investigational or anti-VEGF anticancer therapy prior to study randomization.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
Invasive malignancies that showed activity of disease within 5 years prior to randomization

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Primair doel: Behandeling
Toewijzing: Gerandomiseerd
Masker: Dubbele

Aantal wapens

Wapens en interventies

Deelnemersgroep / Arm	Interventie / Behandeling
Placebo-vergelijker: Placebo matched placebo tablet administered orally once daily for up to 24 months	Geneesmiddel: Placebo Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Experimenteel: Pazopanib Pazopanib tablet administered orally at 800 mg once daily for up to 24 months	Geneesmiddel: Pazopanib Pazopanib 800 mg tablet daily for 104 weeks (24 months)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat	Maatregel Beschrijving	Tijdsspanne
Investigator-assessed Progression-free Survival (PFS) Tijdsspanne: From the date of randomization until the date of progression or death due to any cause (median time of follow-up was 17.9 months for pazopanib and 12.3 months for placebo)	PFS is the interval between the date of randomization and the date of progression, defined by Response Evaluation Criteria in Solid Tumors (RECIST), or death due to any cause. Per RECIST, for target lesions (TLs), disease progression (PD) is defined as >=20% increase in the sum of the longest diameters (LD) of TLs, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of >=1 new lesions. For non-target lesions (NTLs), PD is defined as the appearance of >=1 new lesions and/or unequivocal progression of existing NTLs. Participants (par.) who did not progress/die were censored at the date of last adequate assessment (LAA). Par. who started a new anti-cancer therapy (ACT) prior to radiological progression/death were censored at the date of LAA prior to the new ACT. Par. who progressed/died after an extended period (>=12 months) without adequate assessment (AA) were censored at the date of their last visit with AA prior to progression/death.	From the date of randomization until the date of progression or death due to any cause (median time of follow-up was 17.9 months for pazopanib and 12.3 months for placebo)

Secundaire uitkomstmaten

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Novartis Pharmaceuticals

Medewerkers

GlaxoSmithKline

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

26 mei 2009

Primaire voltooiing (Werkelijk)

8 juli 2012

Studie voltooiing (Werkelijk)

24 augustus 2017

Studieregistratiedata

Eerst ingediend

19 maart 2009

Eerst ingediend dat voldeed aan de QC-criteria

19 maart 2009

Eerst geplaatst (Schatting)

20 maart 2009

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 februari 2021

Laatste update ingediend die voldeed aan QC-criteria

27 januari 2021

Laatst geverifieerd

1 januari 2021

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

110655
2008-004672-50 (EudraCT-nummer)
CPZP034C2301 (Andere identificatie: Novartis)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Eierstokkanker

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Voltooid

Bevacizumab, Capecitabine en Oxaliplatin bij de behandeling van gevorderde dunne darm of ampulla van Vater adenocarcinoom

Adenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaarden

Verenigde Staten
University of Utah
National Cancer Institute (NCI)

Werving

Weerstandstraining +/- Creatine voor patiënten met gemetastaseerde prostaatkanker

Vermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8

Verenigde Staten
Georgetown University
National Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...

Voltooid

Chinese vrouwen en screening op mammografie

Bestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer Society

Verenigde Staten
BioNTech SE
Seventh Framework Programme

Voltooid

RNA-immunotherapie van IVAC_W_bre1_uID en IVAC_M_uID (TNBC-MERIT)

Borstkanker (Triple Negative Breast Cancer (TNBC))

Zweden, Duitsland
Novartis Pharmaceuticals

Voltooid

Werkzaamheidsstudie van MCS110 gegeven met carboplatine en gemcitabine bij vergevorderde triple-negatieve borstkanker (TNBC) (TNBC)

Geavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM's

Frankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
Rashmi Verma, MD
National Cancer Institute (NCI)

Werving

Cyclofosfamide en dexamethason voor de behandeling van gemetastaseerde castratieresistente prostaatkanker

Castratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8

Verenigde Staten
Jonsson Comprehensive Cancer Center

Nog niet aan het werven

Evaluatie van een flexibel doseringsschema van 177Lu-PSMA-617 voor de behandeling van gemetastaseerde castratieresistente prostaatkanker

Prostaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8

Verenigde Staten
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Werving

Fisetin en oefening om kwetsbaarheid bij overlevenden van borstkanker te voorkomen (PROFFi)

Anatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8

Verenigde Staten
University of Southern California
National Cancer Institute (NCI)

Werving

PROACTIEF: Resultaten van chirurgische resecties bij lokaal gevorderde en niet-reseceerbare pancreaskanker na neoadjuvante chemotherapie

Lokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8

Verenigde Staten
Jonsson Comprehensive Cancer Center

Ingetrokken

Focale bestralingstherapie voor de behandeling van prostaatkanker met een laag of gemiddeld risico

Prostaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8

Verenigde Staten

Klinische onderzoeken op Placebo

Galderma R&D

Voltooid

Effect van CD07805/47-gel bij rosacea blozen

Rosacea

Duitsland
SamA Pharmaceutical Co., Ltd

Onbekend

Klinische proeven om de werkzaamheid en veiligheid van HLIM te beoordelen

Acute bronchitis | Acute bovenste luchtweginfectie

Korea, republiek van
National Institute on Drug Abuse (NIDA)

Voltooid

Effecten van cannabistoedieningsroutes op menselijke prestaties en farmacokinetiek

Cannabisgebruik

Verenigde Staten
AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Voltooid

Beoordeling van de veiligheid, verdraagbaarheid en farmacodynamiek na toediening van één dosis AZD8601 aan mannelijke patiënten met diabetes mellitus type II (T2DM)

Mannelijke proefpersonen met diabetes type II (T2DM)

Duitsland
Heptares Therapeutics Limited

Voltooid

Farmacokinetiek van orale capsules bij gezonde Japanse versus blanke proefpersonen (HTL0018318)

Farmacokinetiek | Veiligheid problemen

Verenigd Koninkrijk
Texas A&M University
Nutrabolt

Voltooid

Glycemic Response of a Commercial Food Bar (NB16)

Glucose and Insulin Response
Soroka University Medical Center

Voltooid

Effect of Probiotics in Childhood Abdominal Pain

Buikpijn

Israël
Regado Biosciences, Inc.

Voltooid

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Gezonde vrijwilliger

Verenigde Staten
Longeveron Inc.

Beëindigd

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome (ELPIS)

Hypoplastisch linkerhartsyndroom

Verenigde Staten
Italfarmaco

Voltooid

Klinische studie ter evaluatie van de werkzaamheid en veiligheid van Givinostat bij ambulante patiënten met Becker-spierdystrofie

Becker spierdystrofie

Nederland, Italië

Uitkomstmaat	Maatregel Beschrijving	Tijdsspanne
Overall Survival - Median Tijdsspanne: From the date of randomization until the date of death due to any cause up to approximately 25 months	Overall surival is defined as the interval between the date of randomization and the date of death due to any cause. For participants who did not die, the time to death was censored at the time of last contact.	From the date of randomization until the date of death due to any cause up to approximately 25 months
Overall Survival: Number of Participants Experiencing Death Tijdsspanne: From the date of randomization until the date of death due to any cause up to approximately 25 months	Overall surival is defined as the interval between the date of randomization and the date of death due to any cause. For participants who did not die, the time to death was censored at the time of last contact.	From the date of randomization until the date of death due to any cause up to approximately 25 months
Progression-free Survival Per Gynecologic Cancer Intergroup (GCIG) Criteria Tijdsspanne: From the date of randomization until the date of progression per GCIG criteria or death due to any cause (median time of follow-up was 16.8 months for pazopanib and 11.9 months for placebo)	Progression-free survival by GCIG criteria is defined as the time from the date of randomization to the earliest date of disease progression per GCIG criteria or death due to any cause. Progression is defined according to RECIST but can also be based upon serum CA-125. Progression or recurrence based on serum CA-125 levels are defined on the basis of a progressive serial elevation of serum CA-125, according to the following criteria: (1) participants (par.) with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 >=2x the upper normal limit (UNL) on two occasions at least one week apart or; (2) par. with elevated CA-125 pretreatment, which never normalizes, must show evidence of CA-125 >=2x the nadir value on two occasions at least one week apart or; (3) par. with CA-125 in the normal range pretreatment must show evidence of CA-125 >=2x the UNL on two occasions at least one week apart.	From the date of randomization until the date of progression per GCIG criteria or death due to any cause (median time of follow-up was 16.8 months for pazopanib and 11.9 months for placebo)
3-year Progression-free Survival Tijdsspanne: Up to 3 years after randomization	3-year progression-free survival is defined as the percentage of participants who are progression-free at 3 years from randomization. Progression-free survival is defined as the time from the date of randomization to the earliest date of disease progression (defined by RECIST) or death due to any cause. Per RECIST, for target lesions, disease progression (PD) is defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. For non-target lesions, PD is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.	Up to 3 years after randomization
Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The EORTC QLQ-C30 is a self-reported, 30-item cancer-specific instrument that assesses 15 domains: 5 functional scales (physical, role, emotional, cognitive, and social functioning), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global health status, or quality of life. Global health status is assessed using a 7-item Likert scale, ranging from 1 to 7 ("poor" to "excellent"). Participants were asked to respond to the following questions using the 7-item Likert scale: "How would you rate your overall health during the past week"; "How would you rate your overall quality of life during the past week?" Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures analysis of covariance (ANCOVA).	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Attitude to Disease/Treatment Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV (ovarian)-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses attitude to disease/treatment functional symptoms, among others. Participants were asked to indicate the extent to which they experienced attention to disease/treatment functional problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: How much has your disease been a burden to you?; How much has your treatment been a burden to you?; Were you worried about your future health? Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Body Image Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses body image symptoms, among others. Participants were asked to indicate the extent to which they experienced body image problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Have you felt physically less attractive as a result of your disease or treatment?; Have you been dissatisfied with your body? Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Peripheral Neuropathy (PN) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses peripheral neuropathy symptoms, among others. Participants were asked to indicate the extent to which they experienced peripheral neuropathy symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have tingling hands or feet?; Have you had numbness in your fingers or toes?; Have you felt weak in your arms or legs? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Abdominal (AB)/Gastrointestinal (GI) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses AB/GI symptoms, among others. Participants were asked to indicate the extent to which they experienced AB/GI symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have abdominal pain?; Did you have a bloated feeling in your abdomen/stomach?; Did you have problems with your clothes feeling too tight?; Did you experience any change in bowel habit as a result of your disease or treatment?; Were you troubled by passing wind/gas/flatulence?; Have you felt full too quickly after beginning to eat?; Have you had indigestion/heartburn? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Hormonal/Menopausal Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses hormonal/menopausal symptoms, among others. Participants were asked to indicate the extent to which they experienced hormonal/menopausal symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have hot flashes?; Did you have night sweats? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Sexuality Functional on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses sexual functioning symptoms, among others. Participants were asked to indicate the extent to which they experienced sexual functioning problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: To what extent were you interested in sex?; To what extent were you sexually active?; If sexually active, to what extent was sex enjoyable for you?; If sexually active, did you have a dry vagina during sexual activity? Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA. Data were not analyzed due to low compliance (<50% at Baseline).	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in QLQ-OV-28 Module Other Chemotherapy Side Effects (SE) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses other chemotherapy SE symptoms, among others. Participants were asked to indicate the extent to which they experienced other chemotherapy SE symptoms/problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Have you lost any hair?; If yes, were you upset by the loss of your hair?; Did food/drink taste different from usual?; Did you have aches or pains in your muscles or joints?; Did you have problems with hearing?; Did you urinate frequently?; Have you had skin problems (e.g., itchy, dry)? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA. Data were not analyzed due to low compliance (<50% at Baseline).	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in the EuroQOL EQ-5D (Five Dimensions) Thermometer Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The EuroQol (EQ-5D) questionnaire is a 2-page, generic, preference-based quality of life measure comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score The thermometer score is based on a vertical VAS. The VAS is designed like a thermometer scale on which the best health state the participant can imagine is referenced at 100, and the worst health state the participant can imagine is marked by 0. Based on how good or bad the current health state is, the participant is asked to draw a line across the thermometer scale. For example, a line drawn across 46 on the scale of 0 to 100 would be coded 46. A negative adjusted mean change from Baseline represents a worsening of quality of life. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Change From Baseline in the EQ-5D (Five Dimensions) Utility Score at Week 13 and Months 7, 10, 13, 16, and 25 Tijdsspanne: Baseline; Week 13; Months 7, 10, 13, 16, and 25	The EQ-5D utility score captures health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety and/or depression. Participants indicated the level of perceived problems in each of the five dimensions on three levels: 1, no problems; 2, some problems; 3, an extreme problem. Unique health states were defined by combining response levels from each of the five dimensions. For example, state 11111 indicates no problem on any of the five dimensions, whereas state 11223 indicates no problems with mobility or self-care; some problems with performing usual activities, moderate pain/discomfort; and extreme anxiety/depression. Responses are typically converted into health utilities or valuations on a scale ranging from 0 (worst health) to 1 (perfect health). A negative adjusted mean change from Baseline represents a worsening of quality of life. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.	Baseline; Week 13; Months 7, 10, 13, 16, and 25
Number of Participants With the Indicated Grade 2, 3, and 4 On-therapy Adverse Events Occurring in >=10% of Participants in Either Treatment Arm Tijdsspanne: From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)	An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death.	From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Number of Participants With the Indicated On-therapy Hematology Grade Shifts From Baseline Grade Tijdsspanne: From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)	Hematology toxicities were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death. Participants with a missing Baseline grade were assumed to have a Baseline grade of 0. WBC=White blood cell.	From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Number of Participants With the Indicated On-therapy Chemistry Grade Shifts From Baseline Grade Tijdsspanne: From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)	Hematology toxicities were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death. Participants with a missing Baseline grade were assumed to have a Baseline grade of 0.	From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Number of Participants With the Indicated Treatment-emergent Thyroid-stimulating Hormone (TSH) Elevations Above 5 Million Units Per Liter (MU/L) Tijdsspanne: From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)	Participants were assessed for thyroid function abnormalities. Clinical hypothyroidism is defined as 5 <TSH <=10 MU/L and T4 <lower limit of normal (LLN).	From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Studie Overzicht

Toestand

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Studietype

Inschrijving (Werkelijk)

Fase

Contacten en locaties

Studie Locaties

Deelname Criteria

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

Accepteert gezonde vrijwilligers

Geslachten die in aanmerking komen voor studie

Beschrijving

Studie plan

Hoe is de studie opgezet?

Ontwerpdetails

Aantal wapens

Wapens en interventies

Deelnemersgroep / Arm

Interventie / Behandeling

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat

Maatregel Beschrijving

Tijdsspanne

Secundaire uitkomstmaten

Uitkomstmaat

Maatregel Beschrijving

Tijdsspanne

Medewerkers en onderzoekers

Sponsor

Medewerkers

Publicaties en nuttige links

Algemene publicaties

Studie record data

Bestudeer belangrijke data

Studie start (Werkelijk)

Primaire voltooiing (Werkelijk)

Studie voltooiing (Werkelijk)

Studieregistratiedata

Eerst ingediend

Eerst ingediend dat voldeed aan de QC-criteria

Eerst geplaatst (Schatting)

Updates van studierecords

Laatste update geplaatst (Werkelijk)

Laatste update ingediend die voldeed aan QC-criteria

Laatst geverifieerd

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Beschrijving IPD-plan

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Klinische onderzoeken op Eierstokkanker

Klinische onderzoeken op Placebo

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in China

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties